Cargando…
Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications
BACKGROUND: Monoclonal antibodies (mAbs) represent the most numerous and significant group of biotherapeutics. While mAbs have undoubtedly improved treatment for many chronic diseases, including inflammatory diseases, they are typically expensive for health care systems and patients. Consequently, a...
Autores principales: | Tubic, Biljana, Marković-Peković, Vanda, Jungić, Saša, Allocati, Eleonora, Godman, Brian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413607/ https://www.ncbi.nlm.nih.gov/pubmed/36204505 http://dx.doi.org/10.1177/23992026211027692 |
Ejemplares similares
-
Regulatory aspects of biological medicines in Bosnia and Herzegovina
por: Tubić, Biljana, et al.
Publicado: (2022) -
Trends in Antihypertensive Medicine Utilization in the Republic of Srpska, Bosnia and Herzegovina: An Eleven-Year Follow-Up
por: Kalinić, Dragan, et al.
Publicado: (2022) -
Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study
por: Glamočlija, Una, et al.
Publicado: (2018) -
Rare Diseases and Orphan Drugs Accessibility in Bosnia and Herzegovina
por: Guzvic, Vladmiri, et al.
Publicado: (2018) -
Zoonotic Leishmaniasis, Bosnia and Herzegovina
por: Colella, Vito, et al.
Publicado: (2019)